The FMED ETF is a thematic, actively managed product that selects companies with the potential to change established approaches to medical diagnostics, treatment, and services. It seeks long-term capital growth, focusing on business areas tied to medical innovation such as gene therapy, robotic surgery, and digital health platforms.

It suits long-term investors who want exposure to the growth potential of the medical innovation theme and can tolerate the high volatility that comes with clinical and regulatory variables.

This is an ETF run by Fidelity using an active management approach.

The fund uses bottom-up analysis to pick companies that could drive change in how medical diagnostics, treatment, and services are delivered. It may gain exposure to several paths of medical innovation, including gene therapy, robotic surgery, and digital health platforms, and position weights may vary depending on market conditions and the manager's assessment of company competitiveness.

• Active selection concentrated in medical innovation
• A thematic approach spanning diagnostics, treatment, and services

Assets under management (AUM) stand at $52.1M, and the expense ratio is 0.50% per year.

Because this is a thematic product that reflects Fidelity's management judgment, it is advisable to check not only the fee but also the stock selection criteria, changes in holdings, and trading conditions.

Returns on the medical innovation theme can be highly sensitive to clinical results, approval processes, research and development expectations, and the interest rate environment. The FMED ETF may lean toward specific growth areas rather than healthcare as a whole, so even when markets are stable, price swings may widen on company-specific news.

Fund flows into thematic medical products can be affected by expectations for new drug development, regulatory decisions, and shifts in risk appetite. Trading demand can change quickly in volatile markets, so it is worth checking the FMED ETF's bid-ask spread and trading conditions as well.

Its broad coverage of the medical innovation theme is a strength, but concentrated sector exposure and company-specific events can increase volatility.

Among the products shown in the comparison table, the GRNY ETF follows a large-cap selection strategy, the MAGS ETF concentrates on large technology stocks, and the ARKG ETF centers on the genomic innovation theme, so each has a different character. The XLSR ETF takes a sector rotation approach and the SSUS ETF uses a sector allocation method. When comparing them with the FMED ETF, you should look not only at fee levels and AUM but also at how direct the exposure to medical innovation is, whether the fund is actively managed, and what drives its volatility.

The medical innovation theme reflects both individual companies' research outcomes and regulatory decisions, so it is hard to treat it the same as a broad healthcare product. Before buying, review the product's management approach, distribution history, trading conditions, and currency exposure against your own goals and holding period.

A structure that concentrates on a specific theme can be more sensitive to event-driven swings than a product covering healthcare as a whole. Clinical results, approval decisions, progress in competing technologies, the medical cost environment, and geopolitical variables can affect the outlook and market valuation of holdings, and investors who hold Korean won should also consider exchange rate movements.

The Fidelity Disruptive Medicine ETF can serve as a reference for investors who want to focus on the growth potential of medical innovation companies and understand the product's structure. However, given the lack of distribution history and the risk of thematic concentration, it is advisable to also review how its role differs from a broad healthcare product, its trading conditions, and how much volatility you can accept.